Caris Molecular Intelligence Service examines the genetic and molecular makeup that is unique to each patient’s tumour. By comparing the tumour's information with data from clinical studies from thousands of the world's leading cancer researchers, Caris can help the physician determine which treatments are likely to be most effective and which treatments are likely to be ineffective for each patient. Caris Molecular Intelligence can be used to inform treatment selection when treating aggressive or rare tumors, or refractory disease.
The Prosigna Breast Cancer Prognostic Gene Signature Assay is indicated in female breast cancer patients who have undergone surgery in conjunction with locoregional treatment consistent with standard of care, either as:
Breakthrough genomic cancer testing from a single blood draw Guardant Health has helped thousands of oncologists learn accurate and actionable information about tens of thousands of patients, while avoiding the costs and risks of tissue biopsies. Guardant Health genomic test helps match advanced-cancer patients to approved targeted therapies as well as drugs in clinical trials.
Recent studies have shown that alterations in the BRCA1 and BRCA2 genes are responsible for the majority of hereditary breast and ovarian cancer. Such alterations increase the predisposition for breast and / or ovarian cancer and other cancers as well.